About us
- >
- About us >
- Information >
- Announcement
2023-01-09
ENERGI-F703EB has received a certification letter from the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA),
We are delighted to announce that on January 19, 2023, our company received notification from our consulting firm that our investigational new drug, ENERGI-F703EB, has been granted the Rare Pediatric Disease Designation (RPD) by the Office of Orphan Products Development (OOPD) at the U.S. Food and Drug Administration (FDA).